Targeted Delivery of Immunomodulators to Lymph Nodes
作者: Jamil AzziQian YinMayuko UeharaShunsuke OhoriLi TangKaimin CaiTakaharu IchimuraMartina McGrathOmar MaaroufEirini KefaloyianniScott LoughheadJarolim PetrQidi SunMincheol KwonStefan TulliusUlrich H. von AndrianJianjun ChengReza Abdi
作者单位: 1Transplantation Research Center, Renal Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
2Division of Transplant Surgery and Transplant Surgery Research Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
3Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA
4Department of Materials Science and Engineering, University of Illinois at Urbana−Champaign, Urbana, IL 61820, USA
5Department of Pathology, Clinical Laboratories Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
6The Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA
刊名: Cell Reports, 2016, Vol.15 (6), pp.1202-1213
来源数据库: Elsevier Journal
DOI: 10.1016/j.celrep.2016.04.007
原始语种摘要: Summary(#br)Active-targeted delivery to lymph nodes represents a major advance toward more effective treatment of immune-mediated disease. The MECA79 antibody recognizes peripheral node addressin molecules expressed by high endothelial venules of lymph nodes. By mimicking lymphocyte trafficking to the lymph nodes, we have engineered MECA79-coated microparticles containing an immunosuppressive medication, tacrolimus. Following intravenous administration, MECA79-bearing particles showed marked accumulation in the draining lymph nodes of transplanted animals. Using an allograft heart transplant model, we show that targeted lymph node delivery of microparticles containing tacrolimus can prolong heart allograft survival with negligible changes in tacrolimus serum level. Using MECA79...
全文获取路径: Elsevier  (合作)
分享到:
来源刊物:

×